# Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT05916248** · EARLY_PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 34 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** Personalized neoantigen tumor vaccine
- **BIOLOGICAL:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT05916248
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916248, "Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05916248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*